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A mouse monoclonal ntibody d&ted against one of the major human brain gangliosides, GDlb, has been 
produced. The antibody binds specifically to the carbohydrate structure of GDlb as it does not react with 
structurally related gaagliosides like GMl, GD2, GTl b or Fuc-GMl, or any other ganglioside of human 
brain. The results further indicate that terminal galactose as well as the disialosyl &roup linked to the inner 
galactose moiety are involved in binding to the antibody. 
1. INTRCXXJCTION 
Gangliosides are localized to the outer surface of 
mammalian cell membranes. Their concentration 
and structural composition undergo marked 
changes during development and transformation. 
Gangliosides in the nervous system have been ex- 
tensively studied with regard to structural com- 
position, but little is known about their function 
and exact topographic~ location [2]. Mono~Ional 
antibodies detecting specific gangliosides might be 
a useful tool for the elucidation of such problems 
but gangliosides have generaIIy been poor im- 
m~nogens [3,4]. To our knowledge no specific 
monoclonal antibody directed against any of the 4 
major brain gangliosides has been produced. This 
Abbreviations: Ganglioside abbreviations follow the 
nomenclature system of Svennerholm, IUPAC-IUB 
Commission on Biochemical Nomenclature CBN, The 
Nomenclature of Lipids [I]. GM3, I13NeuAc-LacCer; 
GD3, I13(NeuAc)~-LacCer; GM2, I13NeuAc-GgOses- 
Cer; GD2, I13(NeuA&-GgOse$Zer; GMI, I13NeuAc- 
GgOse.&er; GDla, IV3NeuAc,I13NeuAc-GgOse&er; 
GDlb, I13(NeuAc)z-GgOse&er; Put-GDlb, IV’Fuc, 
I13(NeuA~)~-GgOs~Cer; GTl b, IV3NeuAc,K13(NeuAc)~- 
GgOse&er; and GQlb, IV3(NeuA~)~,I13(NeuAc)*- 
GgOse&er 
paper reports the production and specificity of a 
monoclonal antibody to one of these gangliosides, 
GDlb. 
2. MATERIALS AND METHODS 
2.1. Materials 
The gangliosides used in this study were aIl 
prepared from human brain and the extraction and 
isolation were performed as described f5,6]. Rab- 
bit anti-mouse immunogIobulin, Ig, conjugated 
with horseradish peroxidase (HRP) was purchased 
from Dakopat a/s (Glostrup, Denmark). Affmity- 
purified goat antibody to mouse IgM (cl) from 
Kirkegaard and Perry Laboratories (Gaithersburg, 
MD) was iodinated by the Iodo-gen method [7] to 
a specific activity of 30-6O/rCi/,ug protein. 
2.2. Production and screening of monoclonal 
antibodies 
Purified antigen, ganghoside GDlb, was ad- 
sorbed to acid washed Sa~rna~e~~a min~esuta, the 
ganglioside to bacteria ratio being 1: 10 by wt as 
described [8,9]. The antigen-bacteria complex, cor- 
responding to SOpg bacteria, in phosphate- 
buffered saline (PBS, 0.01 M phosphate buffer, 
pH 7.4,O. 14 M N&I) mixed with an equal volume 
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of Freund’s complete adjuvant was injected sub- 
cutaneously. Booster doses, with the same amount 
of the complex in an equal volume of Freund’s in- 
complete adjuvant, were administered on days 14 
and 23 and fusion with Sp 2/O cells was performed 
on day 26. The antibodies produced were assayed 
for their binding to GDlb with the ELISA-method 
described below. The positive hybrid was cloned 
by limiting dilution and the antibody was found to 
be of the IgM-type. 
2.3. B~~d~~~ assays 
2.3.1. Ganglioside-ELISA 
A modification of the ganglioside-ELISA 
method described by Svennerholm and Holmgren 
[lo] was used and all steps were performed at room 
temperature. Serial dilutions of gangliosides, 
dissolved in 20~1 methanol, were added to the 
wells of a polyvinyl chloride microtiter plate 
(Titerteka Immuno Assay-Plate, Flow Laborato- 
ries, Ayshire, Scotland) and the solution was 
evaporated. Unspecific adsorption was blocked by 
prein~uba~on, 30 min, with 1% bovine serum 
albumin, dissolved in phosphate-buffered saline 
(PBS-BSA), after which the wells were incubated 
for 3-4 h with 50 ~1 monoclonal antibody and 
then with I-IRP-conjugated anti-mouse im- 
munoglobulin, diluted in PBS containing 0.05% 
Tween 20. Bound conjugate was assayed by addi- 
tion of 100 ,ul of substrate (10 ml of 0.1 M citrate 
buffer (pH 4.5), 5 mg o-phenylenediamine, OPD, 
and 4,ul of 30% H202). After 10 min the absor- 
bance was read in a spectrophotometer at 450 nm. 
2.3.2. Radioimmunodet~tion of ganglioside 
antigen on thin-layer plates 
~adioimmun~etection of ganglioside antigens 
separated on thin-layer plates was performed as 
described by Magnani et al. 1111. The gangliosides 
were chromatographed on aluminium-backed high 
performance silica gel plates (Silica gel 60, Merck 
AG, Darmstadt) and overlaid with anti-GDIb 
monoclonal antibody. Bound antibody was 
detected by *251-labelled anti-mouse IgM and the 
thin-layer plate was exposed to X-ray film (XRS, 
Eastman-Kodak, Rochester, NY). 
3. RESULTS AND DISCUSSION 
The fusion of spleen cells from 
24 
Fig.2. Ganglioside-ELISA assay of the binding of the 
anti-GDlb antibody to gangliosides. Isolation of 
gangliosides and the assay procedure are described in 
section 2. (x) GDlb, (D) Fuc-GDlb, (m) GTlb, (0) 
GM1 and (e) GD2. Gangtiosides GD3, GQlb and 
GDla were also tested (not shown) and found to give 
negative results as GTlb, GM1 and GD2. The values 
2 immunized represent he mean of triplicate determinations. 
Fig.1. Schematic drawing of the ganglioside structures 
tested. (a) Galactose, (0) N-acetylgalactosamine, (m) 
glucose, (v) N-acetylneuraminic acid, (Cer) ceramide. 
1 
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mice with mouse myeloma Sp 2/O cells resulted in 
a hybrid that produced a high affinity monoclonal 
antibody to ganglioside GDlb (figs 2 and 3). The 
specificity of the antibody was tested by comparing 
its binding to purified gangliosides with closely 
related structures (see fig.1) and to ganglioside 
mixtures from brain tissue. In the ganglioside- 
ELISA assay (fig.2) half-maximum binding was 
obtained with approx. 25 pmol GDlb, while no 
binding occurred to other gangliosides even when 
200 pmol was added to the wells. Radioim- 
munodetection of the antigen in the ganglioside 
fractions of human normal grey tissue (fig.3) 
revealed no binding to any ganglioside other than 
GDlb which in the lowest concentration cor- 
responded to 4 pmol (fig.3, lane 1). The propor- 
tion of other gangliosides in these mixtures is seen 
in the orcinol stained part of fig.3. 
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Fig.3. Radioimmunodetection of the binding of the anti- 
GDlb antibody to gangliosides from human brain grey 
matter. Isolation of gangliosides and the assay 
procedure are described in section 2. (A) Binding of the 
anti-GDlb antibody to gangliosides from (1) 20 pg, (2) 
100 pg and (3) 500 pg wet wt grey matter, containing 4, 
20 and 100 pmol GDl ganglioside, respectively. (B) 
Orcinol staining of the gangliosides from 1 mg wet wt 
grey matter. 
The anti-GDl b monoclonal antibody appears to 
be specific for the carbohydrate moiety of GDlb. 
The binding activity is completely eliminated by 
removal of any terminal sugar residue such as sialic 
acid (to give GMl) or galactose (GD2) or by the 
addition of sialic acid or fucose to the terminal 
galactose (GTI b) and Fuc-GD 1 b, respectively 
(fig.1). In addition, GD3 had no binding activity, 
which indicates that a disialosyl group bound to 
galactose is not sufficient for binding. 
Monoclonal antibodies with specificity to GD3, 
GM2 and GD2 have been reported [ 12-151 but to 
our knowledge this is the first report of a specific 
monoclonal antibody to any of the major brain 
gangliotetraosyl gangliosides. 
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